Lexeo Therapeutics (LXEO) Current Leases (2022 - 2026)

Lexeo Therapeutics has disclosed Current Leases across 5 years of filings, most recently posting $2.2 million for Q1 2026.

• Current Leases for Q1 2026 came in at $2.2 million, up 315.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 315.93% YoY), and the FY2025 annual result was $518000.0, down 75.33% from the prior year.
• Current Leases came in at $2.2 million for Q1 2026 at Lexeo Therapeutics, up from $518000.0 in the prior quarter.
• In the past five years, Current Leases ranged from a high of $2.3 million in Q4 2022 to a low of $518000.0 in Q4 2025.
• The 5-year median for Current Leases is $2.1 million (2024), against an average of $1.9 million.
• Across the five-year window, Current Leases plunged 75.33% in 2025 and surged 315.93% in 2026, its largest moves.
• Lexeo Therapeutics' Current Leases stood at $2.3 million in 2022, then slipped by 8.75% to $2.1 million in 2023, then increased by 0.62% to $2.1 million in 2024, then slumped by 75.33% to $518000.0 in 2025, then jumped by 318.34% to $2.2 million in 2026.
• The last three Current Leases figures came in at $2.2 million (Q1 2026), $518000.0 (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.